{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:13:44Z","timestamp":1791814424346,"version":"4.3.4"},"reference-count":214,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Antimicrobial resistance (AMR) has reached a critical situation globally, prompting urgent national responses to this escalating crisis, including the prioritization of novel antibiotic research. In 2016, Japan initiated a national AMR action plan that promoted appropriate antibiotic use in the country and encouraged a national environment conducive to mitigation measures. However, tackling AMR remains difficult. From an epidemiological perspective, this challenge now extends beyond severe infections, impacting common community-acquired infections, including uncomplicated urinary tract infections (uUTls) and gonorrhea. In uUTIs, the rising prevalence of extended-spectrum \u03b2-lactamase-producing and fluoroquinolone-resistant Escherichia coli diminishes the effectiveness of current, routinely used oral antibiotics, necessitating an exploration into innovative solutions. Similarly, the growing resistance of Neisseria gonorrhoeae to antibiotics such as azithromycin raises concerns about the efficacy of current therapeutic options for gonorrhea, which is a highly prevalent sexually transmitted infection. In Japan, since the removal of azithromycin as the recommended first-line treatment, there are no oral first-line antibiotics available to treat gonorrhea. Therefore, novel oral antibiotics are urgently needed for both serious and commonly occurring community-acquired infections. This narrative review discusses the limited availability of novel antibiotics in Japan, the distinctive features of the Japanese antibiotic repertoire and AMR epidemiology, and potential alternative oral treatments for community-acquired infections, including uUTIs and gonorrhea. Japan has been making significant advances toward tackling the AMR crisis through an updated national action plan, AMR policy changes, and innovative approaches to developing novel antibiotics. Substantial international cooperation and the engagement of diverse industry sectors are essential to address the pressing issue of AMR.<\/jats:p>","DOI":"10.3390\/antibiotics14080813","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:41:53Z","timestamp":1754653313000},"page":"813","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Current Landscape of Antibiotic Use and Antimicrobial Resistance in Japan: Focusing on Common Infections Including Uncomplicated Urinary Tract Infection and Gonorrhea"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2306-0121","authenticated-orcid":false,"given":"Daisuke","family":"Fukuda","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-3258","authenticated-orcid":false,"given":"Yutaka","family":"Handa","sequence":"additional","affiliation":[{"name":"Specialty Care, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Kayama","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Fujii","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2207-0133","authenticated-orcid":false,"given":"Shinya","family":"Kawamatsu","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Specialty Care, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kawano","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Specialty Care, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Vojtek","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease, GSK, Tokyo 107-0052, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Powell","sequence":"additional","affiliation":[{"name":"Antibiotics, GSK, London WC1A 1DG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4777-7098","authenticated-orcid":false,"given":"Aruni","family":"Mulgirigama","sequence":"additional","affiliation":[{"name":"Antibiotics, GSK, London WC1A 1DG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2509-1052","authenticated-orcid":false,"given":"Yoshiaki","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Center for Infectious Disease Education and Analysis (TCIDEA), Institute of Science Tokyo, Tokyo 113-8510, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s15010-021-01709-3","article-title":"Antibiotics in the pipeline: A literature review (2017\u20132020)","volume":"50","author":"Momattin","year":"2022","journal-title":"Infection"},{"key":"ref_2","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_3","unstructured":"World Health Organization (2024, March 25). Antimicrobial Resistance. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Aljeldah, M.M. (2022). Antimicrobial resistance and its spread is a global threat. Antibiotics, 11.","DOI":"10.3390\/antibiotics11081082"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/IDR.S382617","article-title":"Unmet needs in complicated urinary tract infections: Challenges, recommendations, and emerging treatment pathways","volume":"16","author":"Marantidis","year":"2023","journal-title":"Infect. Drug Resist."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/978-1-4939-9496-0_3","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea","volume":"1997","author":"Unemo","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jgar.2021.11.008","article-title":"A global perspective on improving patient care in uncomplicated urinary tract infection: Expert consensus and practical guidance","volume":"28","author":"Wagenlehner","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1007\/s40121-023-00829-7","article-title":"Decline in antimicrobial consumption and stagnation in reducing disease burden due to antimicrobial resistance in Japan","volume":"12","author":"Tsuzuki","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Kanda, N., Hashimoto, H., Sonoo, T., Naraba, H., Takahashi, Y., Nakamura, K., and Hatakeyama, S. (2020). Gram-negative organisms from patients with community-acquired urinary tract infections and associated risk factors for antimicrobial resistance: A single-center retrospective observational study in Japan. Antibiotics, 9.","DOI":"10.3390\/antibiotics9080438"},{"key":"ref_10","unstructured":"World Health Organization (2025, March 25). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/364996\/9789240062702-eng.pdf?sequence=1."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jiac.2024.01.011","article-title":"Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: Antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus","volume":"30","author":"Wada","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijid.2019.11.009","article-title":"Indications and classes of outpatient antibiotic prescriptions in Japan: A descriptive study using the national database of electronic health insurance claims, 2012\u20132015","volume":"91","author":"Hashimoto","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.juro.2010.04.078","article-title":"Emergence and spread of drug resistant Neisseria gonorrhoeae","volume":"184","author":"Deguchi","year":"2010","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13756-020-00805-7","article-title":"Azithromycin resistant gonococci: A literature review","volume":"9","author":"Derbie","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/cid\/ciz170","article-title":"Widespread use of high-sode ceftriaxone therapy for uncomplicated gonorrhea without reported ceftriaxone treatment failure: Results from 5 years of multicenter surveillance data in China","volume":"70","author":"Han","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jiac.2019.12.001","article-title":"The JAID\/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders","volume":"27","author":"Hamasuna","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1128\/AAC.00325-11","article-title":"Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone","volume":"55","author":"Ohnishi","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jiac.2023.08.003","article-title":"The third nationwide surveillance of antimicrobial susceptibility against Neisseria gonorrhoeae from male urethritis in Japan, 2016\u20132017","volume":"29","author":"Yasuda","year":"2023","journal-title":"J. Infect. Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/jcpt.12202","article-title":"Relationship between drug lag and factors associated with clinical trials in Japan","volume":"39","author":"Ohwaki","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/13697137.2018.1551871","article-title":"The etiology and management of recurrent urinary tract infections in postmenopausal women","volume":"22","author":"Jung","year":"2019","journal-title":"Climacteric"},{"key":"ref_21","unstructured":"World Health Organization (2024, December 11). WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240093461."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41429-023-00629-8","article-title":"Antibiotics in the clinical pipeline as of December 2022","volume":"76","author":"Butler","year":"2023","journal-title":"J. Antibiot."},{"key":"ref_23","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, December 11). Pharmaceuticals and Medical Devices Agency. Available online: https:\/\/www.pmda.go.jp\/english\/."},{"key":"ref_24","unstructured":"US Food and Drug Administration (2024, December 11). US Food and Drug Administration, Available online: https:\/\/www.fda.gov\/."},{"key":"ref_25","unstructured":"European Medicines Agency (2024, December 11). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/homepage."},{"key":"ref_26","unstructured":"World Health Organization (2024, December 11). World Health Organization. Available online: https:\/\/www.who.int\/."},{"key":"ref_27","unstructured":"KEGG: Kyoto Encyclopedia of Genes and Genomes (2024, December 11). KEGG: Kyoto Encyclopedia of Genes and Genomes. Available online: https:\/\/www.genome.jp\/kegg\/."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/dky424","article-title":"Risk analysis of antimicrobial resistance in outpatient urinary tract infections of young healthy adults","volume":"74","author":"Keller","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Takahashi, M., Hagiya, H., Higashionna, T., Nakano, Y., Sato, K., Haruki, Y., Haruki, M., Honda, H., Ogawa, H., and Ueda, K. (2022). Antimicrobial prescription practices for outpatients with uncomplicated cystitis in Japan. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-09946-8"},{"key":"ref_30","unstructured":"JAID\/JSC Guideline Committee (2024, December 11). The JAID\/JSC Guide to Clinical Management of Infectious Diseases 2023. Available online: https:\/\/www.kansensho.or.jp\/modules\/journal\/index.php?content_id=11."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.eururo.2024.03.035","article-title":"European Association of Urology guidelines on urological infections: Summary of the 2024 guidelines","volume":"86","author":"Kranz","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_33","unstructured":"The Government of Japan (2024, December 11). National Action Plan on Antimicrobial Resistance (AMR) 2023\u20132027. Available online: https:\/\/www.mhlw.go.jp\/content\/10900000\/001096228.pdf."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jiac.2020.09.001","article-title":"Epidemiology of antibiotic treatment for uncomplicated cystitis in adults in Japan","volume":"27","author":"Kusama","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Takaya, R., Mori, N., Saito, E., and Ohde, S. (2024). Cost-effectiveness analysis of CTZ\/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan. BMC Health Serv. Res., 24.","DOI":"10.1186\/s12913-024-10883-7"},{"key":"ref_37","unstructured":"Merck (2024, May 23). Merck Receives Positive EU CHMP Opinion for ZERBAXA\u00ae 3g Dose (Ceftolozane and Tazobactam) for the Treatment of Adults with Hospital-Aquired Pneumonia (HAP), Including Ventilator-Associated Pneumonia (VAP). Available online: https:\/\/www.merck.com\/news\/merck-receives-positive-eu-chmp-opinion-for-zerbaxa-3g-dose-ceftolozane-and-tazobactam-for-the-treatment-of-adults-with-hospital-acquired-pneumonia-hap-including-ventilator-associated-pneum\/#:~:text=ZERBAXA%201.5g%20(ceftolozane%201g,%2Dabdominal%20infections%20(cIAI)."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Khankhel, Z.S., Dillon, R.J., Thosar, M., Bruno, C., and Puzniak, L. (2022). Ceftolozane\/tazobactam for the treatment of bacteremia: A systematic literature review (SLR). Ann. Clin. Microbiol. Antimicrob., 21.","DOI":"10.1186\/s12941-022-00528-0"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.15190\/d.2018.1","article-title":"New FDA approved antibacterial drugs: 2015\u20132017","volume":"6","author":"Andrei","year":"2018","journal-title":"Discoveries"},{"key":"ref_40","unstructured":"US Food and Drug Administration (2024, June 01). Delafloxacin\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/208610s000,208611s000lbl.pdf."},{"key":"ref_41","unstructured":"European Medicines Agency (2024, May 23). Quofenix\u2014Delafloxacin. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/quofenix#authorisation-details."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Shi, Z., Zhang, J., Tian, L., Xin, L., Liang, C., Ren, X., and Li, M. (2023). A comprehensive overview of the antibiotics approved in the last two decades: Retrospects and prospects. Molecules, 28.","DOI":"10.3390\/molecules28041762"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2217\/fmb-2019-0089","article-title":"Microbiological profile of ozenoxacin","volume":"14","author":"Morrissey","year":"2019","journal-title":"Future Microbiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14787210.2022.2080656","article-title":"Secnidazole: A treatment for trichomoniasis in adolescents and adults","volume":"20","author":"Muzny","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_45","unstructured":"European Medicines Agency (2024, May 23). Vaborem (Meropenem\/Vaborbactam)\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vaborem#authorisation-details."},{"key":"ref_46","first-page":"528","article-title":"Pharmaceutical approval update","volume":"43","author":"Kaufman","year":"2018","journal-title":"Pharm. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","article-title":"Eravacycline, a newly approved fluorocycline","volume":"38","author":"Lee","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Blanchard, L.S., Armstrong, T.P., Kresken, M., Emery, C.L., Ying, Y.X., Sauvonnet, V., and Zambardi, G. (2023). Multicenter clinical evaluation of ETEST eravacycline for susceptibility testing of Enterobacteriaceae and Enterococci. J. Clin. Microbiol., 61.","DOI":"10.1128\/jcm.01650-22"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s40265-018-1015-2","article-title":"Omadacycline: First global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s40265-019-1053-4","article-title":"Sarecycline: First global approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s40265-021-01471-8","article-title":"Imipenem\/cilastatin\/relebactam: A review in gram-negative bacterial infections","volume":"81","author":"Heo","year":"2021","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Kurihara, D., Matsumoto, S., Kishi, N., Ishii, Y., and Mori, M. (2022). In vitro antibacterial activity of imipenem\/relebactam against clinical isolates in Japan. Microbiol. Spectr., 10.","DOI":"10.1128\/spectrum.02235-21"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: First approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/cid\/ciaa336","article-title":"Lefamulin: A novel semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia","volume":"71","author":"Watkins","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1358\/dot.2020.56.6.3137167","article-title":"Lascufloxacin hydrochloride to treat bacterial infection","volume":"56","author":"Thakare","year":"2020","journal-title":"Drugs Today"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40265-020-01359-z","article-title":"Inhaled liposomal antimicrobial delivery in lung infections","volume":"80","author":"Bassetti","year":"2020","journal-title":"Drugs"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Zangiabadian, M., Malekshahian, D., Arabpour, E., Abadi, S.S.D., Yazarlou, F., Bostanghadiri, N., Centis, R., Aghababa, A.A., Farahbakhsh, M., and Nasiri, M.J. (2022). Amikacin liposome and Mycobacterium avium complex: A systematic review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0279714"},{"key":"ref_58","unstructured":"European Medicines Agency (2024, June 01). Amikacin Liposome\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/arikayce-liposomal-product-information_en.pdf."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028020929988","article-title":"Cefiderocol: A siderophore cephalosporin","volume":"54","author":"Rizk","year":"2020","journal-title":"Ann. Pharmacother."},{"key":"ref_60","unstructured":"US Food and Drug Administration (2024, June 01). Cefiderocol\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/209445s002lbl.pdf."},{"key":"ref_61","unstructured":"European Medicines Agency (2024, June 01). Fetcroja (Cefiderocol)\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/fetcroja-epar-product-information_en.pdf."},{"key":"ref_62","unstructured":"Shionogi (2024, May 23). Regarding the Acquisition of Manufacturing and Marketing Approval for the New Siderophore Cephalosporin Antibiotic Fetroja. Available online: https:\/\/www.shionogi.com\/global\/en\/news\/2023\/11\/20231130.html."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/durlobactam: First approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/d41573-024-00063-x","article-title":"FDA new drug approvals in Q1 2024","volume":"23","author":"Verdin","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_65","unstructured":"European Medicines Agency (2024, June 01). Cefepime\/Enmetazobactam\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/exblifep-epar-product-information_en.pdf."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.mayocp.2020.10.033","article-title":"Addressing antibiotic overuse in the outpatient setting: Lessons from behavioral economics","volume":"96","author":"Mohareb","year":"2021","journal-title":"Mayo Clin. Proc."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Bologna, E., Licari, L.C., Manfredi, C., Ditonno, F., Cirillo, L., Fusco, G.M., Abate, M., Passaro, F., Di Mauro, E., and Crocetto, F. (2024). Carbapenem-resistant Enterobacteriaceae in urinary tract infections: From biological insights to emerging therapeutic alternatives. Medicina, 60.","DOI":"10.3390\/medicina60020214"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jac\/dkad060","article-title":"Gepotidacin: A novel, oral, \u2018first-in-class\u2019 triazaacenaphthylene antibiotic for the treatment of uncomplicated urinary tract infections and urogenital gonorrhoea","volume":"78","author":"Watkins","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Cuningham, W., Perera, S., Coulter, S., Wang, Z., Tong, S.Y.C., and Wozniak, T.M. (2024). Repurposing antibiotic resistance surveillance data to support treatment of recurrent infections in a remote setting. Sci. Rep., 14.","DOI":"10.1038\/s41598-023-50008-4"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13756-022-01121-y","article-title":"Economic burden of antibiotic-not-susceptible isolates in uncomplicated urinary tract infection: Analysis of a US integrated delivery network database","volume":"11","author":"Shafrin","year":"2022","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jiac.2024.03.024","article-title":"Fourth national Japanese antimicrobial susceptibility pattern surveillance program: Bacterial isolates from patients with complicated urinary tract infections","volume":"30","author":"Kobayashi","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"485","DOI":"10.11622\/smedj.2016153","article-title":"Urinary tract infections in adults","volume":"57","author":"Tan","year":"2016","journal-title":"Singapore Med. J."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Salam, M.A., Al-Amin, M.Y., Salam, M.T., Pawar, J.S., Akhter, N., Rabaan, A.A., and Alqumber, M.A.A. (2023). Antimicrobial resistance: A growing serious threat for global public health. Healthcare, 11.","DOI":"10.20944\/preprints202305.0555.v1"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"114378","DOI":"10.1016\/j.addr.2022.114378","article-title":"Novel antimicrobial agents for combating antibiotic-resistant bacteria","volume":"187","author":"Chang","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1185\/03007990802550679","article-title":"Early switch to oral versus intravenous antimicrobial treatment for hospitalized patients with acute pyelonephritis: A systematic review of randomized controlled trials","volume":"24","author":"Vouloumanou","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_76","unstructured":"National Institute for Health and Care Excellence (2024, December 05). Antibacterials, Principles of Therapy. Available online: https:\/\/bnf.nice.org.uk\/treatment-summaries\/antibacterials-principles-of-therapy\/."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7883\/yoken.JJID.2020.005","article-title":"Changing demography of genital chlamydia, gonorrhea, genital herpes, condyloma, and syphilis infections in Japan","volume":"74","author":"Yoshikura","year":"2021","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_78","unstructured":"Centers for Disease Control and Prevention (2024, May 23). Gonorrhea\u2014About Gonorrhea, Available online: https:\/\/www.cdc.gov\/gonorrhea\/about\/index.html."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajog.2016.08.008","article-title":"Sexually transmitted diseases and infertility","volume":"216","author":"Tsevat","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Suay-Garc\u00eda, B., and P\u00e9rez-Gracia, M.T. (2018). Future prospects for Neisseria gonorrhoeae treatment. Antibiotics, 7.","DOI":"10.20944\/preprints201805.0315.v1"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1128\/AAC.01295-13","article-title":"Antimicrobial Resistance and Molecular Typing of Neisseria gonorrhoeae Isolates in Kyoto and Osaka, Japan, 2010 to 2012: Intensified Surveillance after Identification of the First Strain (H041) with High-Level Ceftriaxone Resistance","volume":"57","author":"Shimuta","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/GCO.0b013e3283577e9d","article-title":"Expedited partner therapy for sexually transmitted infections","volume":"24","author":"Hogben","year":"2012","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"45","DOI":"10.18773\/austprescr.2020.008","article-title":"Oral or intravenous antibiotics?","volume":"43","author":"McCarthy","year":"2020","journal-title":"Aust. Prescr."},{"key":"ref_84","first-page":"180","article-title":"Approved antibacterial drugs in the last 10 years: From the bench to the clinic","volume":"1","author":"Sarabia","year":"2023","journal-title":"Explor. Drug Sci."},{"key":"ref_85","unstructured":"Pharmaceuticals and Medical Devices Agency (2025, July 01). List of Approved Drugs April 2004 to March 2025. Available online: https:\/\/www.pmda.go.jp\/files\/000274881.pdf."},{"key":"ref_86","unstructured":"US Food & Drug Aministration (2025, June 04). Sivextro\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/205435s012,205436s007lbl.pdf."},{"key":"ref_87","unstructured":"European Medicines Agency (2025, June 04). Sivextro\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sivextro-epar-product-information_en.pdf."},{"key":"ref_88","unstructured":"European Medicines Agency (2025, June 04). Tenkasi\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tenkasi-epar-product-information_en.pdf."},{"key":"ref_89","unstructured":"US Food and Drug Administration (2025, June 04). ORBACTIV\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/206334s006lbl.pdf."},{"key":"ref_90","unstructured":"Kegg Drug Database (2024, November 07). New Drug Approvals in Japan. Available online: https:\/\/www.kegg.jp\/kegg\/drug\/br08318.html?id=D10779."},{"key":"ref_91","unstructured":"US Food & Drug Aministration (2025, June 04). Xifaxan\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/021361s023lbl.pdf."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s40265-017-0790-5","article-title":"Delafloxacin: First global approval","volume":"77","author":"Markham","year":"2017","journal-title":"Drugs"},{"key":"ref_93","unstructured":"US Food & Drug Aministration (2025, June 04). Sirturo\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/204384s000lbl.pdf."},{"key":"ref_94","unstructured":"European Medicines Agency (2025, June 04). Sirturo\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sirturo-epar-product-information_en.pdf."},{"key":"ref_95","unstructured":"US Food & Drug Aministration (2025, June 04). Dificid\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213138lbl.pdf."},{"key":"ref_96","unstructured":"European Medicines Agency (2025, June 04). Dificlir\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dificlir-epar-product-information_en.pdf."},{"key":"ref_97","unstructured":"US Food & Drug Aministration (2025, June 04). Aemcolo\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/210910s000lbl.pdf."},{"key":"ref_98","unstructured":"Merck (2024, November 28). FDA Approves Merck\u2019s RECARBRIO\u2122 (Imipenem, Cilastatin, and Relebactam) for the Treatment of Adults with Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections Where Limited or No Alternative Treatment Options Are Available. Available online: https:\/\/www.merck.com\/news\/fda-approves-mercks-recarbrio-imipenem-cilastatin-and-relebactam-for-the-treatment-of-adults-with-complicated-urinary-tract-and-complicated-intra-abdominal-bacterial-infections-w\/."},{"key":"ref_99","unstructured":"European Medicines Agency (2024, November 28). Recarbrio. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/recarbrio."},{"key":"ref_100","unstructured":"European Medicines Agency (2024, June 01). Dovprela\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/dovprela-previously-pretomanid-fgk-epar-product-information_en.pdf."},{"key":"ref_101","unstructured":"Insmed (2024, June 01). ARIKAYCE (Amikacin Liposome Inhalation Suspension) Approved by Japan\u2019s Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by MAC Who Did Not Sufficiently Respond to Prior Treatment with MDR. Available online: https:\/\/investor.insmed.com\/2021-03-23-ARIKAYCE-R-amikacin-liposome-inhalation-suspension-Approved-by-Japans-Ministry-of-Health-Labour-and-Welfare-for-the-Treatment-of-Patients-with-NTM-Lung-Disease-Caused-by-MAC-Who-Did-Not-Sufficiently-Respond-to-Prior-Treatment-with-MDR."},{"key":"ref_102","unstructured":"European Medicines Agency (2024, November 28). Exblifep. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep#authorisation-details."},{"key":"ref_103","unstructured":"US Food & Drug Aministration (2025, March 21). FDA Approves New Treatment for Uncomplicated Urinary Tract Infections in Adult Women Who Have Limited or No Alternative Oral Antibiotic Treatment Options, Available online: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections-adult-women-who-have-limited-or-no."},{"key":"ref_104","unstructured":"GSK (2025, March 21). Blujepa (Gepotidacin) [Package Insert], Available online: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218230s000lbl.pdf."},{"key":"ref_105","unstructured":"AbbVie (2025, May 16). Emblaveo (Aztreonam and Avibactam)\u2014Highlights of Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/217906Orig1s000lbl.pdf."},{"key":"ref_106","unstructured":"AbbVie (2025, May 16). Emblaveo (Aztreonam and Avibactam)\u2014Summary of Product Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/emblaveo-epar-product-information_en.pdf."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Aoki, W., Uwamino, Y., Kamoshita, Y., Inose, R., Nagata, M., Hasegawa, N., and Matsushita, H. (2025). In vitro activity of aztreonam-avibactam combination against blood culture isolates of Stenotrophomonas maltophilia in Japan before the launch of ceftazidime-avibactam. Microbiol. Spectr., 13.","DOI":"10.1128\/spectrum.03316-24"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.44.2.283-286.2000","article-title":"Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"44","author":"Tomioka","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e00700-17","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem-resistant Gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2710.2009.01099.x","article-title":"Approval of new drugs 1999\u20132007: Comparison of the US, the EU and Japan situations","volume":"35","author":"Tsuji","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrd.2016.155","article-title":"Accelerating global innovation to address antibacterial resistance: Introducing CARB-X","volume":"15","author":"Outterson","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_112","unstructured":"European Medicines Agency (2025, March 21). Tripartite Meeting Held Between EMA, FDA and PMDA at EMA, London, on 1\u20132 September 2016 to Discuss Regulatory Approaches for the Evaluation of Antibacterial Agents. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/tripartite-meeting-held-between-ema-fda-and-pmda-ema-london-1-2-september-2016-discuss-regulatory-approaches-evaluation-antibacterial-agents_en.pdf."},{"key":"ref_113","unstructured":"European Medicines Agency (2025, March 21). Meeting Summary\u2014Second Tripartite Meeting Held Between EMA, PMDA and FDA to Discuss Regulatory Approaches for the Evaluation of Antibacterial Agents. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/other\/meeting-summary-second-tripartite-meeting-held-between-ema-pmda-and-fda-discuss-regulatory-approaches-evaluation-antibacterial-agents_en.pdf."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"A655","DOI":"10.1016\/j.jval.2017.08.1556","article-title":"Price comparison of new drugs in Japan, EU and US","volume":"20","author":"Maruyama","year":"2017","journal-title":"Value Health"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/2168479017706716","article-title":"Comparison of new drug accessibility and price between Japan and major European countries","volume":"51","author":"Takayama","year":"2017","journal-title":"Ther. Innov. Regul. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1080\/14787210.2022.2142118","article-title":"A narrative review on drug development for the management of antimicrobial- resistant infection crisis in Japan: The past, present, and future","volume":"20","author":"Ohashi","year":"2022","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Japan Cooperative Clinical Study Group for Co-trimoxazole (1973). Trimethoprim-sulfamethoxazole in the treatment of bacterial infections: Report of clinical trials in Japan. J. Infect. Dis., 128, S629\u2013S635.","DOI":"10.1093\/infdis\/128.Supplement_3.S629"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1017\/ash.2023.2","article-title":"Prescribed daily-dose-based metrics of oral antibiotic use for hospitalized children in Japan","volume":"3","author":"Mimura","year":"2023","journal-title":"Antimicrob. Steward. Healthc. Epidemiol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cmi.2019.11.028","article-title":"Oral amoxicillin and amoxicillin-clavulanic acid: Properties, indications and usage","volume":"26","author":"Huttner","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jiac.2020.09.026","article-title":"In vitro and in vivo antibacterial activity of nitrofurantoin against clinical isolates of E. coli in Japan and evaluation of biological cost of nitrofurantoin resistant strains using a mouse urinary tract infection model","volume":"27","author":"Nakagawa","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_121","unstructured":"US Food and Drug Administration (2024, May 23). FDA Approves New Treatment for Uncomplicated Urinary Tract Infections, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-treatment-uncomplicated-urinary-tract-infections."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jgar.2016.07.002","article-title":"Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013)","volume":"7","author":"Muraki","year":"2016","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jiac.2018.01.003","article-title":"Trends and patterns of national antimicrobial consumption in Japan from 2004 to 2016","volume":"24","author":"Tsutsui","year":"2018","journal-title":"J. Infect. Chemother."},{"key":"ref_124","unstructured":"Atarashi, S. (2018). Research and Development of Quinolones in Daiichi Sankyo Co., Ltd.. Infect. Update, 47\u201357. Available online: https:\/\/infectweb.com\/app\/uploads\/en\/2018\/03\/03_SpeFeature.pdf."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Fischer, J., and Ganellin, C.R. (2006). Analogue-based drug discovery, Wiley-VCH Verlag GmbH & Co. KGaA.","DOI":"10.1002\/3527608001"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1128\/AAC.00049-07","article-title":"Activity of faropenem against middle ear fluid pathogens from children with acute otitis media in Costa Rica and Israel","volume":"51","author":"Stone","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1107\/S2056989018010770","article-title":"Crystal structure of tebipenem pivoxil","volume":"74","author":"Tang","year":"2018","journal-title":"Acta Crystallogr. E Crystallogr. Commun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/07853890.2020.1861322","article-title":"A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection","volume":"53","author":"Li","year":"2021","journal-title":"Ann. Med."},{"key":"ref_129","unstructured":"Kyorin Pharmaceutical (2024, June 01). KYORIN and Nanjing Neiwa Faith Signed License Agreement for Lascufloxacin in China. Available online: https:\/\/www.kyorin-pharm.co.jp\/en\/news\/KYORIN%20and%20Nanjing%20Neiwa%20Faith%20Signed%20License%20Agreement%20for%20Lascufloxacin%20in%20China.pdf."},{"key":"ref_130","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, December 10). Summary of Investigation Results Tosufloxacin Tosilate Hydrate (for Oral Use). Available online: https:\/\/www.pmda.go.jp\/files\/000223964.pdf."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e02612-20","DOI":"10.1128\/AAC.02612-20","article-title":"A Phase 1 study of the safety, tolerability, and pharmacokinetics of biapenem in healthy adult subjects","volume":"65","author":"Griffith","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2165\/00003495-200363090-00005","article-title":"Panipenem\/betamipron","volume":"63","author":"Goa","year":"2003","journal-title":"Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2165\/11207380-000000000-00000","article-title":"Sitafloxacin: In bacterial infections","volume":"71","author":"Keating","year":"2011","journal-title":"Drugs"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e01971-17","DOI":"10.1128\/AAC.01971-17","article-title":"In vitro activity of lascufloxacin against Streptococcus pneumoniae with mutations in the quinolone resistance-determining regions","volume":"62","author":"Murata","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2131\/jts.48.149","article-title":"Effects of early-life tosufloxacin tosilate hydrate administration on growth rate, neurobehavior, and gut microbiota at adulthood in male mice","volume":"48","author":"Hasegawa","year":"2023","journal-title":"J. Toxicol. Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/bco2.286","article-title":"Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies","volume":"5","author":"Thompson","year":"2024","journal-title":"BJUI Compass"},{"key":"ref_137","unstructured":"European Medicines Agency (2024, November 27). Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/quinolone-fluoroquinolone-containing-medicinal-products."},{"key":"ref_138","unstructured":"US Food & Drug Aministration (2025, July 01). FDA Drug Safety Communication: FDA Updates Warnings for Oral and Injectable Fluoroquinolone Antibiotics Due to Disabling Side Effects, Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"q183","DOI":"10.1136\/bmj.q183","article-title":"Fluoroquinolone antibiotics: Prescribe only as last resort, says UK regulator","volume":"384","author":"Iacobucci","year":"2024","journal-title":"BMJ"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.35772\/ghm.2019.01017","article-title":"National action plan on antimicrobial resistance (AMR) 2016\u20132020 and relevant activities in Japan","volume":"1","author":"Ohmagari","year":"2019","journal-title":"Glob. Health Med."},{"key":"ref_141","unstructured":"Daiichi Sankyo Company Ltd (2024, June 01). Broad-Spectrum Oral Antibacterial Agent Gracevit\u00ae Tablets 50 mg\/fine Granules 10% Receives Approval for Manufacturing and Marketing. Available online: https:\/\/www.daiichisankyo.com\/files\/news\/pressrelease\/pdf\/005667\/news2008_01_28_107_en.pdf."},{"key":"ref_142","first-page":"98","article-title":"Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory infections","volume":"60","author":"Kobayashi","year":"2007","journal-title":"Jpn. J. Antibiot."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Grayson, M.L., Cosgrove, S., Crowe, S., Hope, W., McCarthy, J., Mills, J., Mouton, J.W., and Paterson, D. (2017). Faropenem. Kucers\u2019 the Use of Antibiotics: A Clinical Review of Antibacterials, Antifungal, Antiparasitic, and Antiviral Drugs, CRC Press. [7th ed.]. Chapter 41.","DOI":"10.1201\/9781498747967"},{"key":"ref_144","unstructured":"Daiichii-Sankyo Company Ltd. (2024, December 10). Reference Data (FY2005 1st Half). Available online: https:\/\/www.daiichisankyo.com\/files\/news\/ir\/pdf\/005171\/ser2005_11_07_19_03.pdf."},{"key":"ref_145","unstructured":"Synapse by Patsnap (2024, December 10). Panipenem\/Betamipron. Available online: https:\/\/synapse.patsnap.com\/drug\/9875dd7137f049ad8b9e5180bf7777f6#approval."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/14787210.2018.1496821","article-title":"Tebipenem, the first oral carbapenem antibiotic","volume":"16","author":"Jain","year":"2018","journal-title":"Expert Rev. Anti Infect. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"dlac125","DOI":"10.1093\/jacamr\/dlac125","article-title":"A systematic scoping review of faropenem and other oral penems: Treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems","volume":"4","author":"Gandra","year":"2022","journal-title":"JAC Antimicrob. Resist."},{"key":"ref_148","unstructured":"Sumitomo Pharma (2024, November 28). Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong. Available online: https:\/\/www.sumitomo-pharma.com\/news\/20170609-1.html."},{"key":"ref_149","unstructured":"Smith, H.Z., Hollingshead, C.M., and Kendall, B. (2024). Carbapenem-Resistant Enterobacterales, StatPearls Publishing."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"184","DOI":"10.5001\/omj.2019.37","article-title":"WHO global priority pathogen list: A bibliometric analysis of Medline-PubMed for knowledge mobilization to infection prevention and control practices in Bahrain","volume":"34","author":"Asokan","year":"2019","journal-title":"Oman Med. J."},{"key":"ref_151","first-page":"247","article-title":"Biapenem American Cyanamid Co","volume":"1","author":"Dax","year":"1998","journal-title":"IDrugs"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s004670050386","article-title":"Nephrotoxicity of beta-lactam antibiotics: Mechanisms and strategies for prevention","volume":"11","author":"Tune","year":"1997","journal-title":"Pediatr. Nephrol."},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Ueda, T., Takesue, Y., Nakajima, K., Ichiki, K., Ishikawa, K., Yamada, K., Tsuchida, T., Otani, N., Takahashi, Y., and Ishihara, M. (2023). Correlation between antimicrobial resistance and the wide diverse use of broad-spectrum antibiotics by the Antimicrobial Stewardship Program in Japan. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15020518"},{"key":"ref_154","unstructured":"World Health Organization (2025, June 05). Global Action Plan on Antimicrobial Resistance. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/193736\/9789241509763_eng.pdf?sequence=1."},{"key":"ref_155","unstructured":"World Health Organization (2025, June 05). Library of AMR National Action Plans. Available online: https:\/\/www.who.int\/teams\/surveillance-prevention-control-AMR\/national-action-plan-monitoring-evaluation\/library-of-national-action-plans."},{"key":"ref_156","unstructured":"The Government of Japan (2024, December 11). National Action Plan on Antimicrobial Resistance (AMR) 2016\u20132022. Available online: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000138942.pdf."},{"key":"ref_157","unstructured":"The White House (2025, June 04). United States: National Action Plan for Combating Antibiotic-Resistant Bacteria. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/antimicrobial-resistance\/amr-spc-npm\/nap-library\/national-action-plan-for-combating-antibiotic-resistant-bacteria.pdf?sfvrsn=bf707027_1&download=true."},{"key":"ref_158","unstructured":"HM Government (2025, June 04). United Kingdom of Great Britain and Northern Ireland: UK Five Year Antimicrobial Resistance Strategy. Available online: https:\/\/cdn.who.int\/media\/docs\/default-source\/antimicrobial-resistance\/amr-spc-npm\/nap-library\/uk_amr_5_year_national_action_plan-2019-24.pdf?sfvrsn=614851a5_1&download=true."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"106829","DOI":"10.1016\/j.ijantimicag.2023.106829","article-title":"Promotion of antimicrobial stewardship following issuance of the antimicrobial resistance national action plan in Japan: A systematic review of 2016\u20132020","volume":"62","author":"Honda","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_160","unstructured":"Government of Japan Ministry of Health Labour and Welfare Health Service Bureau Tuberculosis and Infectious Diseases Control Division (2024, April 01). Manual of Antimicrobial Stewardship. Available online: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000193504.pdf."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijid.2020.11.158","article-title":"The effects of Japan\u2019s National Action Plan on antimicrobial resistance on antimicrobial use","volume":"103","author":"Kusama","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"102657","DOI":"10.1016\/j.jiac.2025.102657","article-title":"Current status and challenges of health economic evaluations related to antimicrobial stewardship in Japan: A scoping review up to 2023","volume":"31","author":"Goto","year":"2025","journal-title":"J. Infect. Chemother."},{"key":"ref_163","unstructured":"The Task Force for Combating Antibiotic-Resistant Bacteria (2025, June 04). National Action Plan for Combating Antibiotic-Resistant Bacteria: YEAR 5 Report, Available online: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/d5d01eb69710588247eb2aef3a46c118\/HHS_ASPE_CARB_Report_Year5.pdf."},{"key":"ref_164","unstructured":"GOV.UK (2024, November 28). Fluoroquinolone Antibiotics: New Restrictions and Precautions for Use Due to Very Rare Reports of Disabling and Potentially Long-Lasting or Irreversible Side Effects, Available online: https:\/\/www.gov.uk\/drug-safety-update\/fluoroquinolone-antibiotics-new-restrictions-and-precautions-for-use-due-to-very-rare-reports-of-disabling-and-potentially-long-lasting-or-irreversible-side-effects."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e3236","DOI":"10.1136\/bmj.e3236","article-title":"Carbapenem antibiotics for serious infections","volume":"344","author":"Hawkey","year":"2012","journal-title":"BMJ."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijantimicag.2018.10.011","article-title":"Infections by multidrug-resistant gram-negative bacteria: What\u2019s new in our arsenal and what\u2019s in the pipeline?","volume":"53","author":"Koulenti","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Fukuda, D., Haines, A.S., Song, Z., Murphy, A.C., Hothersall, J., Stephens, E.R., Gurney, R., Cox, R.J., Crosby, J., and Willis, C.L. (2011). A natural plasmid uniquely encodes two biosynthetic pathways creating a potent anti-MRSA antibiotic. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018031"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: Advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.cbpa.2020.07.010","article-title":"Natural product discovery through microbial genome mining","volume":"60","author":"Kenshole","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ja.2013.121","article-title":"Screening and biological activities of pedopeptins, novel inhibitors of LPS produced by soil bacteria","volume":"67","author":"Kozuma","year":"2014","journal-title":"J. Antibiot."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Wasan, H., Singh, D., Reeta, K.H., and Gupta, Y.K. (2023). Landscape of push funding in antibiotic research: Current status and way forward. Biology, 12.","DOI":"10.3390\/biology12010101"},{"key":"ref_172","unstructured":"The Joint Programming Initiative on Antimicrobial Resistance (2024, December 19). Japan. Available online: https:\/\/www.jpiamr.eu\/about\/jpiamr-members\/japan\/."},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Schurer, M., Patel, R., van Keep, M., Horgan, J., Matthijsse, S., and Madin-Warburton, M. (2023). Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE\u2019s subscription-style payment model. Front. Med. Technol., 5.","DOI":"10.3389\/fmedt.2023.1010247"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"e852","DOI":"10.1016\/S2666-5247(23)00250-1","article-title":"Why is the UK subscription model for antibiotics considered successful?","volume":"4","author":"Glover","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_175","unstructured":"World Health Organization (2025, June 04). Japan\u2019s AMR Response 2013\u20132025: Developing, Implementing and Evaluating National AMR Action Plans. Available online: https:\/\/iris.who.int\/bitstream\/handle\/10665\/380481\/9789290620792-eng.pdf?sequence=1."},{"key":"ref_176","unstructured":"Shrestha, J., Zahra, F., and Cannady, J.P. (2024). Antimicrobial stewardship, StatPearls Publishing."},{"key":"ref_177","unstructured":"Sinawe, H., and Casadesus, D. (2024). Urine culture, StatPearls Publishing."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Holm, A., Cordoba, G., S\u00f8rensen, T.M., Jessen, L.R., Siersma, V., and Bjerrum, L. (2015). Point of care susceptibility testing in primary care\u2014does it lead to a more appropriate prescription of antibiotics in patients with uncomplicated urinary tract infections? Protocol for a randomized controlled trial. BMC Fam. Pract., 16.","DOI":"10.1186\/s12875-015-0322-x"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Gajic, I., Kabic, J., Kekic, D., Jovicevic, M., Milenkovic, M., Mitic Culafic, D., Trudic, A., Ranin, L., and Opavski, N. (2022). Antimicrobial susceptibility testing: A comprehensive review of currently using methods. Antibiotics, 11.","DOI":"10.3390\/antibiotics11040427"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13756-022-01170-3","article-title":"Impact of suboptimal or inappropriate treatment on healthcare resource use and cost among patients with uncomplicated urinary tract infection: An analysis of integrated delivery network electronic health records","volume":"11","author":"Shafrin","year":"2022","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_181","doi-asserted-by":"crossref","unstructured":"Alkhawaldeh, R., Abu Farha, R., Abu Hammour, K., and Alefishat, E. (2022). Optimizing antimicrobial therapy in urinary tract infections: A focus on urine culture and sensitivity testing. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1058669"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/cid\/ciz1031","article-title":"Resistance-guided antimicrobial therapy using doxycycline\u2013moxifloxacin and doxycycline\u20132.5 g azithromycin for the treatment of mycoplasma genitalium infection: Efficacy and tolerability","volume":"71","author":"Durukan","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Adawiyah, R.A., Bradshaw, C.S., Vodstrcil, L.A., Fairley, C.K., Zhang, L., and Ong, J.J. (2024). Cost-effectiveness of resistance-guided therapy for Mycoplasma genitalium in Australia. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-63056-1"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/cid\/ciy477","article-title":"Outcomes of resistance-guided sequential treatment of Mycoplasma genitalium infections: A prospective evaluation","volume":"68","author":"Read","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/cid\/ciaa596","article-title":"Resistance-guided treatment of gonorrhea: A prospective clinical study","volume":"73","author":"Klausner","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jiac.2023.11.002","article-title":"Cumulative antibiogram preparation among hospitals participating in the Japan Surveillance for Infection Prevention and Healthcare Epidemiology","volume":"30","author":"Ishioka","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.euf.2015.12.010","article-title":"Integrated biosensor assay for rapid uropathogen identification and phenotypic antimicrobial susceptibility testing","volume":"3","author":"Altobelli","year":"2017","journal-title":"Eur. Urol. Focus."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1007\/s40121-023-00862-6","article-title":"Efficacy and safety of gepotidacin as treatment of uncomplicated urogenital gonorrhea (EAGLE-1): Design of a randomized, comparator-controlled, Phase 3 study","volume":"12","author":"Perry","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1473-3099(19)30116-1","article-title":"Solithromycin versus ceftriaxone plus azithromycin for the treatment of uncomplicated genital gonorrhoea (SOLITAIRE-U): A randomised phase 3 non-inferiority trial","volume":"19","author":"Chen","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1093\/cid\/ciac738","article-title":"Sulopenem or ciprofloxacin for the treatment of uncomplicated urinary tract infections in women: A Phase 3, randomized trial","volume":"76","author":"Dunne","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref_191","unstructured":"ClinicalTrials.gov (2024, December 06). Zoliflodacin in Uncomplicated Gonorrhoea, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03959527?term=NCT03959527&rank=1."},{"key":"ref_192","unstructured":"ClinicalTrials.gov (2024, December 17). Oral Sulopenem-Etzadroxil\/Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03354598?term=NCT03354598&rank=1."},{"key":"ref_193","unstructured":"ClinicalTrials.gov (2024, May 23). A Study to Investigate the Efficacy and Safety with Gepotidacin in Japanese Female Participants with Uncomplicated Urinary Tract Infection (Acute Cystitis) (EAGLE-J), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05630833."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: An oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.anl.2023.11.008","article-title":"Efficacy, safety, and tissue penetration of solithromycin in Japanese patients with otorhinolaryngological infections","volume":"51","author":"Kurono","year":"2024","journal-title":"Auris Nasus Larynx"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): Two randomised, controlled, double-blind, double-dummy, Phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against Staphylococcus aureus gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: Genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"S642","DOI":"10.1093\/ofid\/ofaa439.1433","article-title":"1249. Genetic evidence that gepotidacin shows well-balanced dual targeting against DNA gyrase and topoisomerase IV in Neisseria gonorrhoeae","volume":"7","author":"Chan","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"e0152522","DOI":"10.1128\/aac.01525-22","article-title":"Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020)","volume":"67","author":"Arends","year":"2023","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1093\/jac\/dky162","article-title":"In vitro activity of the novel triazaacenaphthylene gepotidacin (GSK2140944) against MDR Neisseria gonorrhoeae","volume":"73","author":"Jacobsson","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Koeth, L.M., DiFranco-Fisher, J.M., and Scangarella-Oman, N.E. (2023). Analysis of the effect of urine on the in vitro activity of gepotidacin and levofloxacin against Escherichia coli, Staphylococcus epidermidis, and Staphylococcus saprophyticus. Diagn. Microbiol. Infect. Dis., 106.","DOI":"10.1016\/j.diagmicrobio.2023.115946"},{"key":"ref_204","unstructured":"GSK (2024, April 18). EAGLE-1 Phase III Data Show Potential for Gepotidacin as a New Oral Treatment Option for Uncomplicated Urogenital Gonorrhoea (GC) amid Growing Resistance to Existing Treatments. Available online: www.gsk.com\/en-gb\/media\/press-releases\/eagle-1-phase-iii-data-show-potential-for-gepotidacin-as-a-new-oral-treatment-option-for-uncomplicated-gc\/."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","article-title":"Design of two Phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants","volume":"11","author":"Perry","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2146\/ajhp160934","article-title":"Solithromycin: A novel ketolide antibiotic","volume":"74","author":"Buege","year":"2017","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1128\/AAC.00090-09","article-title":"Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101","volume":"53","author":"Waites","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1128\/AAC.01662-09","article-title":"CEM-101 activity against gram-positive organisms","volume":"54","author":"Woosley","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.jiac.2018.09.003","article-title":"Antimicrobial activity of solithromycin and levofloxacin against a murine pneumonia mixed-infection model caused by Streptococcus pneumoniae and anaerobic bacteria","volume":"25","author":"Kato","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_210","unstructured":"National Institute of Allergy and Infectious Diseases (2024, May 23). NIH Statement on Preliminary Efficacy Results of First-in-Class Gonorrhea Antibiotic Developed Through Public-Private Partnership, Available online: https:\/\/www.niaid.nih.gov\/news-events\/nih-statement-preliminary-efficacy-results-first-class-gonorrhea-antibiotic-developed#:~:text=A%20single%20dose%20of%20a,GARDP)%2C%20the%20study%20sponsor."},{"key":"ref_211","doi-asserted-by":"crossref","unstructured":"Jacobsson, S., Golparian, D., Oxelbark, J., Kong, F.Y.S., Da Costa, R.M.A., Franceschi, F., Brown, D., Louie, A., Drusano, G., and Unemo, M. (2023). Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1291885"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1155\/2006\/707296","article-title":"Where have all the antibiotics gone?","volume":"17","author":"Davies","year":"2006","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41579-019-0293-3","article-title":"Antibiotic development\u2014economic, regulatory and societal challenges","volume":"18","author":"Balasegaram","year":"2020","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/813\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:26:18Z","timestamp":1760034378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/8\/813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":214,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["antibiotics14080813"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14080813","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}